Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
10
×
life sciences
national blog main
national top stories
new york top stories
10
×
boston blog main
new york blog main
boston top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
clinical trials
biotech
national
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
alnylam pharmaceuticals
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
patisiran
roche
tafamidis
cancer
ceo
What
medicine
10
×
drug
fda
approved
alnylam
new
patients
bio
cancer
friday
making
oks
post
rna
rnai
roundup
specifically
time
uses
afternoon
ago
alnylam’s
announced
approve
approves
atrophy
awaits
backs
bets
big
biological
biopharma
bosley's
bosley’s
brexanolone
bridge
bucks
car
cas
celgene
Language
unset
Current search:
fda
×
medicine
×
" new york top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum